First-Ever Clinical Program in Peeling Skin Syndrome Advances as FDA Clears Quoin’s QRX003
A rare disease with no approved treatments and no prior formal clinical development now has its first company-sponsored clinical program.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has cleared its Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome (PSS). The clearance paves the way for a Phase 2 study expected to begin in the second half of 2026. According to the company, this is the first IND ever submitted to and cleared by the FDA for PSS, establishing the first formal, company-sponsored clinical program for the condition.
No Approved Treatments, and No Prior Development Program
Peeling Skin Syndrome is a rare genetic disease characterized by continuous shedding of the outer layers of the skin, accompanied by chronic pain and intense itching. Until now, patients have had no approved therapies and no structured clinical development. The FDA’s clearance is the first formal step toward building a clinical pathway for this underserved condition.
A Portfolio Built on Two Platform Assets
PSS is now the second FDA-cleared indication for Quoin’s lead asset QRX003, alongside the ongoing Netherton Syndrome program. Rather than developing one-off drugs for single diseases, the company is building a portfolio around two platform assets, QRX003 and QRX009, that can address multiple rare and orphan indications sharing similar underlying needs. QRX003 is advancing across a family of rare genetic skin diseases, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and ichthyosis. QRX009 extends the same platform approach to additional rare conditions. Together, the two assets broaden the company’s potential reach beyond any single disease.
Positive Read-Through to the Netherton Syndrome Program
The FDA’s feedback carries implications for Quoin’s lead indication. The agency raised no safety concerns about the proposed Phase 2 study design or duration of dosing in PSS, which the company views as an encouraging signal as it prepares for its pivotal Phase 3 trial in Netherton Syndrome. Separately, the company cited an ongoing investigator-led pediatric study in which a patient achieved clinically meaningful improvement by Week 12 across key severity and quality-of-life measures, with no adverse events after more than 15 months of continuous treatment.
Timelines Converge in the Second Half of 2026
The back half of 2026 concentrates a significant share of Quoin’s clinical activity into a single window. The company plans to initiate both the Phase 2 study in PSS and the pivotal Phase 3 study in Netherton Syndrome during that period, with a potential NDA filing for Netherton Syndrome in 2027 and a targeted first approval in PSS as early as 2028. For investors, the clearance expands QRX003 into a second rare disease indication while reinforcing Quoin’s strategy of building value around platform assets that can address multiple orphan conditions with high unmet need.
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
